Clinical Cancer Research Prevention Award AACR Membership
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bhoumik, A.
Right arrow Articles by Ronai, Z.'e.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bhoumik, A.
Right arrow Articles by Ronai, Z.'e.
Clinical Cancer Research Vol. 7, 331-342, February 2001
© 2001 American Association for Cancer Research


Experimental Therapeutics, Preclinical Pharmacology

Activating Transcription Factor 2-derived Peptides Alter Resistance of Human Tumor Cell Lines to Ultraviolet Irradiation and Chemical Treatment1

Anindita Bhoumik, Vladimir Ivanov and Ze’ev Ronai2

Ruttenberg Cancer Center, Mount Sinai School of Medicine, New York, New York 10029

Activating transcription factor 2 (ATF2) and its kinase, p38, play an important role in the resistance of melanoma to radiation and chemotherapy. Whereas ATF2 up-regulates the expression of tumor necrosis factor {alpha}, which serves as a survival factor in late-stage melanoma cells, p38 attenuates Fas expression via inhibition of nuclear factor-{kappa}B. We investigated whether ATF2-derived peptides could be used to alter the sensitivity of human melanoma cells to radiation and chemical treatment. Of four 50-amino acid peptides tested, the peptide spanning amino acids 50–100 elicited the most efficient increase in the sensitivity of human melanoma cells to UV radiation or treatment by mitomycin C, Adriamycin, and verapamil, or UCN-01, as revealed by apoptosis assays. Sensitization by ATF2 peptide was also observed in the MCF7 human breast cancer cells but not in early-stage melanoma or melanocytes, or in in vitro-transformed 293T cells. When combined with an inhibitor of p38 catalytic activity, cells expressing amino acids 50–100 of ATF2 exhibited an increase in the degree of programmed cell death, indicating that combined targeting of ATF2 and p38 kinases is sufficient to induce apoptosis in late-stage melanoma cells. The ability of the peptide to increase apoptosis coincided with increased cell surface expression of Fas, which is the primary death-signaling cascade in these late-stage melanoma cells. Overall, our studies identified a critical domain of ATF2 that may be used to sensitize tumor cells to radiation and chemical treatment-induced apoptosis and that can induce apoptosis when combined with inhibition of ATF2 kinase, p38.




This article has been cited by other articles:


Home page
J. Immunol.Home page
B. Samten, J. C. Townsend, S. E. Weis, A. Bhoumik, P. Klucar, H. Shams, and P. F. Barnes
CREB, ATF, and AP-1 Transcription Factors Regulate IFN-{gamma} Secretion by Human T Cells in Response to Mycobacterial Antigen
J. Immunol., August 1, 2008; 181(3): 2056 - 2064.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
A. Bhoumik, B. Fichtman, C. DeRossi, W. Breitwieser, H. M. Kluger, S. Davis, A. Subtil, P. Meltzer, S. Krajewski, N. Jones, et al.
Suppressor role of activating transcription factor 2 (ATF2) in skin cancer
PNAS, February 5, 2008; 105(5): 1674 - 1679.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. Abbas, A. Bhoumik, R. Dahl, S. Vasile, S. Krajewski, N. D.P. Cosford, and Z. A. Ronai
Preclinical Studies of Celastrol and Acetyl Isogambogic Acid in Melanoma
Clin. Cancer Res., November 15, 2007; 13(22): 6769 - 6778.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
S. Yang, Y. Yang, J. Raycraft, H. Zhang, S. Kanan, Y. Guo, Z. Ronai, I. Hellstrom, and K. E. Hellstrom
Melanoma cells transfected to express CD83 induce antitumor immunity that can be increased by also engaging CD137
PNAS, April 6, 2004; 101(14): 4990 - 4995.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. J. Berger, H. M. Kluger, N. Li, E. Kielhorn, R. Halaban, Z.'e. Ronai, and D. L. Rimm
Subcellular Localization of Activating Transcription Factor 2 in Melanoma Specimens Predicts Patient Survival
Cancer Res., December 1, 2003; 63(23): 8103 - 8107.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
H. Liu, E.-S. Lee, C. Gajdos, S. T. Pearce, B. Chen, C. Osipo, J. Loweth, K. McKian, A. De Los Reyes, L. Wing, et al.
Apoptotic Action of 17{beta}-Estradiol in Raloxifene-Resistant MCF-7 Cells In Vitro and In Vivo
J Natl Cancer Inst, November 5, 2003; 95(21): 1586 - 1597.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
S.-G. Cho, A. Bhoumik, L. Broday, V. Ivanov, B. Rosenstein, and Z.'e. Ronai
TIP49b, a Regulator of Activating Transcription Factor 2 Response to Stress and DNA Damage
Mol. Cell. Biol., December 15, 2001; 21(24): 8398 - 8413.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.